SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Nuvilex, Inc. (OTCQB: NVLX) announced today that as part of its acquisition of SG Austria, Nuvilex will benefit from grant funding previously awarded to SG Austria for its live-cell encapsulation activities and other projects. The total grant funding awarded to SG Austria is approximately $1.5 million. Management expects much of the remaining funding will be utilized over the next 12 months to study, create, and advance preclinical studies of the Company’s signature technology platform, Cell In A Box.
